Author:
Swenson J M,Wallace R J,Silcox V A,Thornsberry C
Abstract
Broth microdilution MICs were determined for 258 clinical isolates of Mycobacterium fortuitum (3 biovariants) and M. chelonae (2 subspecies) with amikacin, tobramycin, cefoxitin, doxycycline, erythromycin, and sulfamethoxazole-trimethoprim and with several new beta-lactams and aminoglycosides and ciprofloxacin. Variations in susceptibility by and within species subgroups confirm the need for susceptibility testing against clinically important strains.
Publisher
American Society for Microbiology
Subject
Infectious Diseases,Pharmacology (medical),Pharmacology
Reference25 articles.
1. Brosbe E. A. P. T. Sugihara C. R. Smith and L. Hyde. 1965. Experimental drug studies on Mycobacterium fortuitum p. 733-736. Antimicrob. Agents Chemother. 1964.
2. In vitro susceptibility of Mycobacterium fortuitum and Mycobacterium chelonei to cefoxitin;Casal M.;Tubercle,1982
3. In vitro susceptibility of Mycobacterium fortuitum and M. chelonei to sisomicin, gentamicin, and tobramycin;Casal M. J.;Ann. Microbiol. (Paris),1983
4. In vitro susceptibility of Mycobacterium fortuitum to N-formimidoyl thienamycin and several cephamycins;Cynamon M. H.;Antimicrob. Agents Chemother.,1982
5. In vitro susceptibility of Mycobacterium fortuitum to amoxicillin or cephalothin in combination with clavulanic acid;Cynamon M. H.;Antimicrob. Agents Chemother.,1983
Cited by
246 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献